Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: Possible applications to Alzheimer disease

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 5, 2013, Pages 712-721

  Lazar, Adina N ^a,b   Mourtas, Spyridon ^c   Youssef, Ihsen ^b   Parizot, Christophe ^d   Dauphin, Aurélien ^d   Delatour, Benoît ^b   Antimisiaris, Sophia G ^c,e   Duyckaerts, Charles ^a,b  

^a Lab Neuropathologie R Escourolle   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c UNIVERSITY OF PATRAS   (Greece)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

Alzheimer disease; Amyloid deposits; Amyloid peptide; Curcumin; Curcumin conjugated nanoliposomes

Indexed keywords

ALZHEIMER DISEASE; AMYLOID DEPOSITS; AMYLOID PEPTIDES; CURCUMIN; NANOLIPOSOMES;

DRUG DELIVERY; GLYCOPROTEINS; MAMMALS; MOLECULES; NEURODEGENERATIVE DISEASES; PEPTIDES; PHYSIOLOGY; TISSUE; TOXICITY;

DEPOSITS;

AMYLOID BETA PROTEIN; CURCUMIN; LIPOSOME;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NEOCORTEX; NONHUMAN; SOLUBILITY; STAIN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTOPSY; COLORING AGENTS; CURCUMIN; HUMANS; LIPOSOMES; MICE; NANOPARTICLES; NEOCORTEX; PEPTIDE FRAGMENTS;

MUS;

EID: 84879460570     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.11.004     Document Type: Article

References (38)

1. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012, 8:1-13.
2. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.
3. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009, 50:1887-1894.
4. Koronyo-Hamaoui M., Koronyo Y., Ljubimov A.V., Miller C.A., Ko M.K., Black K.L., et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011, 54(Suppl. 1):S204-S217.
5. Lee I., Yang J., Lee J.H., Choe Y.S. Synthesis and evaluation of 1-(4-[(18)F]fluoroethyl)-7-(4'-methyl)curcumin with improved brain permeability for beta-amyloid plaque imaging. Bioorg Med Chem Lett 2011, 21:5765-5769.
6. Ray B., Lahiri D.K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009, 9:434-444.
7. Yanagisawa D., Amatsubo T., Morikawa S., Taguchi H., Urushitani M., Shirai N., et al. In vivo detection of amyloid beta deposition using (1)F magnetic resonance imaging with a (1)F-containing curcumin derivative in a mouse model of Alzheimer's disease. Neuroscience 2011, 184:120-127.
8. Costantino L., Tosi G., Ruozi B., Bondioli L., Vandelli M.A., Forni F. Chapter 3-colloidal systems for CNS drug delivery. Prog Brain Res 2009, 180:35-69.
9. Jolck R.I., Feldborg L.N., Andersen S., Moghimi S.M., Andresen T.L. Engineering liposomes and nanoparticles for biological targeting. Adv Biochem Eng Biotechnol 2011, 125:251-280.
10. Re F., Cambianica I., Sesana S., Salvati E., Cagnotto A., Salmona M., et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol 2010, 156:341-346.
11. Roney C., Kulkarni P., Arora V., Antich P., Bonte F., Wu A., et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005, 108:193-214.
12. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res 2010, 27:1759-1771.
13. Webb M.S., Rebstein P., Lamson W., Bally M.B. Liposomal drug delivery: recent patents and emerging opportunities. Recent Pat Drug Deliv Formul 2007, 1:185-194.
14. Ghaghada K.B., Colen R.R., Hawley C.R., Patel N., Mukundan S. Liposomal contrast agents in brain tumor imaging. Neuroimaging Clin N Am 2010, 20:367-378.
15. Kakinuma K., Tanaka R., Takahashi H., Sekihara Y., Watanabe M., Kuroki M. Drug delivery to the brain using thermosensitive liposome and local hyperthermia. Int J Hyperthermia 1996, 12:157-165.
16. Zhang X., Xie J., Li S., Wang X., Hou X. The study on brain targeting of the amphotericin B liposomes. J Drug Target 2003, 11:117-122.
17. Usta M., Wortelboer H.M., Vervoort J., Boersma M.G., Rietjens I.M., van Bladeren P.J., et al. Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of these conjugates in Caco-2 cells. Chem Res Toxicol 2007, 20:1895-1902.
18. Stewart J.C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980, 104:10-14.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
20. Montine T.J., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Dickson D.W., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012, 123:1-11.
21. The mouse brain in stereotaxic coordinates 1997, Academic Press, San Diego. K.B.J. Franklin, G. Paxinos (Eds.).
22. Khopde S.M., Priyadarsini K.I., Palit D.K., Mukherjee T. Effect of solvent on the excited-state photophysical properties of curcumin. Photochem Photobiol 2000, 72:625-631.
23. Kim S.H., Gwon S.Y., Burkinshaw S.M., Son Y.A. The photo- and electrophysical properties of curcumin in aqueous solution. Spectrochim Acta A Mol Biomol Spectrosc 2010, 76:384-387.
24. Mukerjee A., Sorensen T.J., Ranjan A.P., Raut S., Gryczynski I., Vishwanatha J.K., et al. Spectroscopic properties of curcumin: orientation of transition moments. J Phys Chem B 2010, 114:12679-12684.
25. Nardo L., Andreoni A., Bondani M., Masson M., Haukvik T., Tonnesen H.H. Studies on curcumin and curcuminoids. XLVI. Photophysical properties of dimethoxycurcumin and bis-dehydroxycurcumin. J Fluoresc 2012, 22:597-608.
26. Zhang C., Browne A., Child D., Tanzi R.E. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 2010, 285:28472-28480.
27. Weibel Stereological methods. Practical methods for biological morphometry 1979, Academic Press, London.
28. Hardy J. Testing times for the "amyloid cascade hypothesis". Neurobiol Aging 2002, 23:1073-1074.
29. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
30. Garcia-Alloza M., Borrelli L.A., Rozkalne A., Hyman B.T., Bacskai B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007, 102:1095-1104.
31. Ran C., Xu X., Raymond S.B., Ferrara B.J., Neal K., Bacskai B.J., et al. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. J Am Chem Soc 2009, 131:15257-15261.
32. Burgos-Moron E., Calderon-Montano J.M., Salvador J., Robles A., Lopez-Lazaro M. The dark side of curcumin. Int J Cancer 2010, 126:1771-1775.
33. Basnet P., Hussain H., Tho I., Skalko-Basnet N. Liposomal delivery system enhances anti-inflammatory properties of curcumin. J Pharm Sci 2012, 101:598-609.
34. Kunwar A., Barik A., Pandey R., Priyadarsini K.I. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim Biophys Acta 2006, 1760:1513-1520.
35. Li L., Braiteh F.S., Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104:1322-1331.
36. Mourtas S., Canovi M., Zona C., Aurilia D., Niarakis A., La Ferla B., et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials 2011, 32:1635-1645.
37. Taylor M., Moore S., Mourtas S., Niarakis A., Re F., Zona C., et al. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Abeta peptide. Nanomedicine 2011, 7:541-550.
38. Mancuso C., Siciliano R., Barone E. Curcumin and Alzheimer disease: this marriage is not to be performed. J Biol Chem 2011, 286:le3.